description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-3.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


status: Public on Nov 06 2014

type: RNA

city: Pittsburgh

first: Victoria

last: Plamadeala

state: Pennsylvania

address: 2516 Jane St

country: USA

institute: Precision Therapeutics

description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-3.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

hyb_protocol: Fragmented and labelled cDNA was hybridized to HG-U133 Plus 2.0 microarray (Affymetrix) at 45C for 18 hours at a rotation speed of 60rpm. Arrays were washed and stained using the Affymetrix GeneChip Hybridization, Wash & Stain kit in the Affymetrix FS450Dx2 Fluidics Station.

scan_protocol: Arrays were scanned on the GeneChip System 3000Dx v.2 (Affymetrix) using the HG-U133+2.0 protocol.

data_processing: RefRMA

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: Lung

label_protocol: Extracted total RNA was amplified using the Ovation Pico WTA System V2 (NuGEN Technologies, Inc.) and then fragmented and labelled with the Encore Biotin Module (NuGEN Technologies, Inc.).

growth_protocol: Immediately upon surgical extraction, specimens were either flash frozen and stored at -80C or placed in RNAL. Specimens were not subjected to any type of growth environment between surgical extraction and total RNA extraction.

extract_protocol: Total RNA was extracted from each specimen via a phenol-chloroform protocol.

treatment_protocol: Specimens were treated in 2 different ways to ensure stabilization of genomic material, notably total RNA.  Specimens were either flash frozen and then stored at -80C or placed immediately in RNAL.

tag: study

value: PRECISION STUDY

tag: tissue

value: non-small-cell lung carcinoma

tag: patient

value: Patient 2 in 1st sub-study (Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)

tag: risk

value: high


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-3.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F004-1.2A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)

value: low


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-2.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;Low Risk;Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F005-3.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F004-1.2B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-2.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-3.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-1.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-1.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-2.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-1.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-3.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F003-2.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-3.3C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: PRECISION STUDY

value: Patient 1 in 1st sub-study (Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-3.3B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: non-small-cell lung carcinoma

value: Patient 1 in 1st sub-study (Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-3.3A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)

value: high


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F002-1.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-3.2B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-3.1B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F004-1.3A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)

value: low


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-3.2A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-3.1C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-3.1A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-2.2A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-2.2B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-2.3C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32-004-2.1B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: PRECISION STUDY

value: Patient 1 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-1.3C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: non-small-cell lung carcinoma

value: Patient 1 in 1st sub-study (Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-004-2.1A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-1.3B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: high


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-2.2C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;Low Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-005-1.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-1.2A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-1.2B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 2 in 1st sub-study;Low Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-005-2.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)

value: low


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-1.3A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32-004-1.1B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32F001-2.3B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;Low Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-006-1.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 3 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32-004-2.1C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-003-2.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: PRECISION STUDY

value: Patient 3 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-004-1.1A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: non-small-cell lung carcinoma

value: Patient 1 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 3 in 1st sub-study;High Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-003-1.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 3 in 1st sub-study;Low Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-006-2.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-002-2.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 2 in 1st sub-study;High Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-002-1.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32-001-2.1C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-3.2C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 3;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32-001-2.1B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)

value: high


description:
PRECISION STUDY::Patient 2 in 1st sub-study;Low Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F005-2.3)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 2 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0118.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: EQUIVALENCE STUDY

tag: specimen

tag: specimen treatment

value: Fresh Frozen


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-001-2.1A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0118.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0116.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32-001-1.1A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3)


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0112.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0115.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0116.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0113.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0117.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32F001-1.2C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 2;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32-001-1.1B)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
PRECISION STUDY::Patient 1 in 1st sub-study;Low Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.3 (M32-004-1.1C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: low


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0113.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0106.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0107.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0105.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0106.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0112.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 1;Day 1;NuGen lot 1211216-A;Encore lot1211102-B;Rep.1 (M32-001-1.1C)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0108.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0105.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0111.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0107.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0115.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0117.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0104.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0111.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0104.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0101.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.2 (S0867F0103.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.2 (S0867F0102.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0099.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: RNALater


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0094.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0095.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0102.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0100.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0090.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0097.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0100.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0093.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0098.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;Fresh Frozen;'Rep.1 (S0867F0101.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0095.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0093.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0103.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0087.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0088.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0090.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0088.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0089.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;Fresh Frozen;'Rep.1 (S0867F0108.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0089.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0099.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0094.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0098.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
PRECISION STUDY::Patient 1 in 1st sub-study;High Risk;Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2 (M32F001-2.3A)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Patient 1 in 1st sub-study (Operator 2;Day 3;NuGen lot 1211216-A;Encore lot1211102-B;Rep.2)


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0086.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.